company background image
GSD logo

Devonian Health Group TSXV:GSD Stock Report

Last Price

CA$0.13

Market Cap

CA$18.5m

7D

-3.8%

1Y

0%

Updated

21 Nov, 2024

Data

Company Financials

Devonian Health Group Inc.

TSXV:GSD Stock Report

Market Cap: CA$18.5m

GSD Stock Overview

Engages in the development of botanical drugs. More details

GSD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Shares are highly illiquid

Earnings have declined by 3.8% per year over past 5 years

Does not have a meaningful market cap (CA$19M)


Devonian Health Group Inc. Competitors

Nextleaf Solutions

CNSX:OILS

CA$11.6m

Numinus Wellness

TSX:NUMI

CA$12.9m

Avicanna

TSX:AVCN

CA$27.3m

Red White & Bloom Brands

CNSX:RWB

CA$23.5m

Price History & Performance

Summary of all time highs, changes and price drops for Devonian Health Group
Historical stock prices
Current Share PriceCA$0.13
52 Week HighCA$0.35
52 Week LowCA$0.075
Beta1.22
11 Month Change-19.35%
3 Month Change-21.88%
1 Year Change0%
33 Year Change-68.75%
5 Year Change-3.85%
Change since IPO-84.38%

Recent News & Updates

Recent updates

Is Devonian Health Group (CVE:GSD) A Risky Investment?

Mar 20
Is Devonian Health Group (CVE:GSD) A Risky Investment?

Is Devonian Health Group (CVE:GSD) Using Debt In A Risky Way?

Dec 01
Is Devonian Health Group (CVE:GSD) Using Debt In A Risky Way?

Is Devonian Health Group (CVE:GSD) Weighed On By Its Debt Load?

Aug 18
Is Devonian Health Group (CVE:GSD) Weighed On By Its Debt Load?

Does Devonian Health Group (CVE:GSD) Have A Healthy Balance Sheet?

Apr 24
Does Devonian Health Group (CVE:GSD) Have A Healthy Balance Sheet?

Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?

Mar 02
Does Devonian Health Group's (CVE:GSD) CEO Salary Compare Well With Industry Peers?

Shareholder Returns

GSDCA PharmaceuticalsCA Market
7D-3.8%-6.1%0.7%
1Y0%-22.3%21.7%

Return vs Industry: GSD exceeded the Canadian Pharmaceuticals industry which returned -22.3% over the past year.

Return vs Market: GSD underperformed the Canadian Market which returned 21.7% over the past year.

Price Volatility

Is GSD's price volatile compared to industry and market?
GSD volatility
GSD Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement8.3%
10% most volatile stocks in CA Market17.6%
10% least volatile stocks in CA Market2.9%

Stable Share Price: GSD's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine GSD's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20157Luc Gregoiregroupedevonian.com

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.

Devonian Health Group Inc. Fundamentals Summary

How do Devonian Health Group's earnings and revenue compare to its market cap?
GSD fundamental statistics
Market capCA$18.53m
Earnings (TTM)-CA$3.17m
Revenue (TTM)CA$9.75m

1.9x

P/S Ratio

-5.8x

P/E Ratio

Is GSD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GSD income statement (TTM)
RevenueCA$9.75m
Cost of RevenueCA$6.73m
Gross ProfitCA$3.02m
Other ExpensesCA$6.19m
Earnings-CA$3.17m

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.021
Gross Margin30.95%
Net Profit Margin-32.50%
Debt/Equity Ratio15.3%

How did GSD perform over the long term?

See historical performance and comparison